Dakota Boston, MD
Endocrinology, Diabetes & Metabolism · Shreveport, LANPI 1962899971
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,419 of the $3,636 with a category attached, or 66.5%. 25 manufacturers reported payments, led by Medtronic at 46.2% of the total. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in LA, where the typical reported total is $3,044.
Across 118 payments — averaging $30.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Amgen$411
- Novo Nordisk$296
- Lilly USA, LLC$146
- Daiichi Sankyo Inc.$131
- Corcept Therapeutics$121
- plus $851 from 19 others
What the payments were for
- Travel & lodging$1,21733%
- Food & beverage$2,41967%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 19 | $1,681 |
| Amgen(2 entities) | 12 | $411 |
| Novo Nordisk | 12 | $296 |
| Lilly USA, LLC | 9 | $146 |
| Daiichi Sankyo Inc. | 8 | $131 |
| Corcept Therapeutics | 7 | $121 |
| Dexcom, Inc. | 4 | $92 |
| Boehringer Ingelheim | 6 | $89 |
| Bayer | 5 | $81 |
| Xeris Pharmaceuticals, Inc. | 4 | $80 |
| Tandem Diabetes Care, Inc. | 5 | $78 |
| Insulet Corporation | 3 | $64 |
| Abbott | 3 | $51 |
| Acadia Pharmaceuticals Inc | 3 | $45 |
| Pfizer | 3 | $44 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $41 |
| GSK | 2 | $26 |
| AstraZeneca | 2 | $26 |
| AbbVie | 1 | $25 |
| Johnson & Johnson | 2 | $23 |
| Ascendis Pharma Endocrinology Inc | 1 | $21 |
| BETA Bionics, Inc. | 1 | $21 |
| Sequel Med Tech, LLC | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$1,212
- EVENITY$125
- TEPEZZA$125
- RYBELSUS$120
How this compares
$3,636 in reported general payments places this provider in the 50th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
See all endocrinology, diabetes & metabolism providers in Louisiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 229 | $267,390 |
| MounjaroTirzepatide | 133 | $178,754 |
| JardianceEmpagliflozin | 130 | $96,238 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 63 | $82,374 |
| FarxigaDapagliflozin Propanediol | 59 | $60,749 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 40 | $54,364 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 56 | $50,636 |
| Humalog Kwikpen U-200Insulin Lispro | 13 | $46,362 |
| TrulicityDulaglutide | 27 | $39,375 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 52 | $37,795 |
| SynjardyEmpagliflozin/Metformin Hcl | 34 | $27,426 |
| Tresiba Flextouch U-100Insulin Degludec | 32 | $27,075 |
| Tresiba Flextouch U-200Insulin Degludec | 21 | $26,436 |
| Repatha SureclickEvolocumab | 19 | $22,040 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 15 | $18,582 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Xultophy 100-3.6, Fiasp, Novolog | $296 | $306,470271 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $146 | $226,387192 claims |
| Boehringer IngelheimJardiance, Synjardy, Tradjenta, Glyxambi | $89 | $140,801186 claims |
| AstraZenecaFarxiga | $26 | $60,74959 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Admelog | $15 | $52,91667 claims |
| MerckJanuvia | $13 | $15,24617 claims |
| AbbVieSynthroid | $25 | $4,63077 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
Other endocrinology, diabetes & metabolism in Shreveport
- Michelle ChicoShreveport$12K
- Binod PokhrelShreveport$3K
- Sirisha Reddy ThambuluruShreveport$3K
- Timothy GilbertBaton Rouge$985K
- Vivian FonsecaNew Orleans$658K
- Abdul KhanHammond$587K
- Marideli ScanlanMarrero$444K
- Justin FontenotLafayette$397K
- Ileana TandronSlidell$205K
- Lane FreyThibodaux$202K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.